HCMV modulation of cellular PI3K/AKT/mTOR signaling: New opportunities for therapeutic intervention?

Author: AltmanAaron M, ChanGary, MahmudJamil, Nikolovska-ColeskaZaneta

Paper Details 
Original Abstract of the Article :
Human cytomegalovirus (HCMV) remains a major public health burden domestically and abroad. Current approved therapies, including ganciclovir, are only moderately efficacious, with many transplant patients suffering from a variety of side effects. A major impediment to the efficacy of current anti-HC...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元:
https://pubmed.ncbi.nlm.nih.gov/30668978

データ提供:米国国立医学図書館(NLM)

HCMV and the PI3K/Akt/mTOR Signaling Axis: A New Frontier in Antiviral Therapy?

In the ever-evolving battle against viruses, we're constantly seeking new strategies to outsmart these cunning invaders. This study focuses on the human cytomegalovirus (HCMV), a formidable adversary that poses a significant public health threat. The authors explore the intricate relationship between HCMV and the PI3K/Akt/mTOR signaling axis, a vital cellular pathway involved in cell growth and survival. They propose that targeting this pathway might be a promising avenue for developing new antiviral therapies, especially against the dormant stages of HCMV infection, which have traditionally been difficult to target.

Targeting the PI3K/Akt/mTOR Pathway

The study suggests that exploiting the unique modifications HCMV imparts on the PI3K/Akt/mTOR pathway during quiescent infection of monocytes could be a promising strategy for antiviral intervention. This approach offers a potential avenue for disrupting the virus's life cycle, particularly during its dormant stages. The authors delve into the potential of targeting this pathway, highlighting the advantages of this approach compared to conventional antiviral strategies that primarily focus on the lytic stage of viral replication.

A New Era of Antiviral Treatment

This research, like a desert oasis offering hope in the fight against viruses, suggests a new frontier in antiviral therapy. By targeting the PI3K/Akt/mTOR pathway, we might be able to develop novel treatments that effectively address both the active and dormant stages of HCMV infection. This holds immense promise for improving patient outcomes and combating this persistent public health challenge.

Dr.Camel's Conclusion

In our relentless quest to control viral infections, this study offers a fresh perspective, urging us to explore the intricacies of cellular pathways and their interactions with viruses. By targeting the PI3K/Akt/mTOR axis, we could be on the cusp of a new era of antiviral therapy, effectively combating the silent threat of HCMV and other persistent viral infections.

Date :
  1. Date Completed 2020-03-13
  2. Date Revised 2021-12-04
Further Info :

Pubmed ID

30668978

DOI: Digital Object Identifier

NIHMS1519890

Related Literature

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.